On Feb. 24, 2026, Ardelyx (NASDAQ:ARDX) President and CEO Michael Raab reported the sale of 41,666 shares of Common Stock for approximately $261,000, according to a SEC Form 4 filing.
|
Metric |
Value |
|---|---|
|
Shares sold (direct) |
41,666 |
|
Transaction value |
$261,000 |
|
Post-transaction shares (direct) |
1,836,153 |
|
Post-transaction shares (indirect) |
25,364 |
|
Post-transaction value (direct ownership) |
~$12M |
Transaction value based on SEC Form 4 weighted average purchase price ($6.25). Post-transaction value based on closing price of Feb. 24 ($6.56).
-
What is the context of the derivative activity in this filing?
This sale involved an option exercise of 20,833 shares prior, as mentioned in the SEC filing. -
How did the transaction affect Raab’s overall ownership and liquidity profile?
Following the sale, Raab retains 1,836,153 shares directly and 25,364 shares indirectly.
|
Metric |
Value |
|---|---|
|
Price (as of Feb. 28, 2026) |
$6.55 |
|
Market capitalization |
$1.61 billion |
|
Revenue (TTM) |
$407.32 million |
|
Net Loss (TTM) |
$61.60 |
Ardelyx is a biotech company focused on innovative therapies for patients with gastrointestinal conditions and chronic kidney disease. Along with a strong client base in the U.S., it also partners with pharmaceutical entities in Canada, China, and Japan.
On Feb. 19, 2026, Ardelyx reported its Q4 earnings for fiscal year 2025, showing positive growth, including now having four consecutive years of revenue growth and a declining net loss. Its therapy treatment, IBSRELA, which is for patients with irritable bowel syndrome with constipation, has been highly successful. Its XPHOZAH treatment, which helps patients on dialysis manage chronic kidney disease, has also been a popular staple of the company.
On Feb. 24, the pharmaceutical company announced a multi-year partnership with the Ladies Professional Golf Association (LPGA), aiming to educate and mobilize women in health. Ardelyx, now an official corporate pharmaceutical marketing partner of the LPGA Tour, hopes to support women’s digestive health, including those with conditions such as irritable bowel syndrome and constipation.
The company’s stock price grew approximately 18% in 2025, and is currently up 15% this year. However, investors may want to monitor the growing speculation that Ardelyx could be acquired, as rumors suggest the Indian pharmaceutical company Zydus Lifesciences is exploring a majority stake in Ardelyx. This remains just rumors for now, but it is something to keep an eye on.
Before you buy stock in Ardelyx, consider this:
